{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T13:51:21Z","timestamp":1659102681050},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T00:00:00Z","timestamp":1307059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s00262-011-1044-0","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T06:00:55Z","timestamp":1307080855000},"page":"1397-1403","source":"Crossref","is-referenced-by-count":2,"title":["Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers"],"prefix":"10.1007","volume":"60","author":[{"given":"Goki","family":"Shindo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Onda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoju","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigenori","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,3]]},"reference":[{"key":"1044_CR1","first-page":"640","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Davis TE, Creech RH, McFadden ET, Tormey DC, Carbone PP, Horton J (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:640\u2013655","journal-title":"Am J Clin Oncol"},{"key":"1044_CR2","first-page":"3321","volume":"24","author":"K Egawa","year":"2004","unstructured":"Egawa K (2004) Immuno-cell therapy of cancer in Japan. Anticancer Res 24:3321\u20133326","journal-title":"Anticancer Res"},{"key":"1044_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-0774.2004.tb00014.x","volume":"17","author":"K Egawa","year":"2004","unstructured":"Egawa K (2004) On the safety assurance of all processing carried out in medical institutions for autologous immuno-cell therapy. Hum Cell 17:1\u20136","journal-title":"Hum Cell"},{"key":"1044_CR4","first-page":"2461","volume":"22","author":"S Goto","year":"2002","unstructured":"Goto S, Shirotani N, Hatakeyama M, Tagami C, Arakawa H, Kuwata E, Noguchi K, Egawa K (2002) Clinical benefit of non-toxic therapy in patients with advanced cancer (Opinion). Anticancer Res 22:2461\u20132464","journal-title":"Anticancer Res"},{"key":"1044_CR5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1749-0774.2003.tb00154.x","volume":"16","author":"M Nieda","year":"2003","unstructured":"Nieda M, Tomiyama M, Egawa K (2003) Ex vivo enhancement of antigen-presenting function of dendritic cells and its application for DC-based immunotherapy. Hum Cell 16:199\u2013204","journal-title":"Hum Cell"},{"key":"1044_CR6","first-page":"3742","volume":"25","author":"S Goto","year":"2005","unstructured":"Goto S, Kaneko T, Miyamoto Y, Eriguchi M, Kato A, Akeyama T, Fujimoto K, Tomonaga M, Egawa K (2005) Combined immunocell therapy using activated lymphocytes and monocytes-derived dendritic cells for malignant melanoma. Anticancer Res 25:3742\u20133746","journal-title":"Anticancer Res"},{"key":"1044_CR7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00262-004-0560-6","volume":"54","author":"PE Novellino","year":"2005","unstructured":"Novellino PE, Castelli C, Parmiani G (2005) A listing of human antigens recognized by T cells:March 2004 update. Cancer Immunol Immunother 54:187\u2013207","journal-title":"Cancer Immunol Immunother"},{"key":"1044_CR8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono G, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Eukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 361:947\u2013957","journal-title":"New Engl J Med"},{"key":"1044_CR9","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","volume":"27","author":"B Kaufman","year":"2009","unstructured":"Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, R\u00e9vil C\u00e9dric, Jones A (2009) Trastuzumab plus anastorozol versus anastrozol alone for treatment of postmenopausal women with human epidermal growth factor receptor2-posittive, hormone receptor-positive metastatic breast cancer:Results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529\u20135537","journal-title":"J Clin Oncol"},{"key":"1044_CR10","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909\u2013915","journal-title":"Nat Med"},{"key":"1044_CR11","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1349-7006.2004.tb02182.x","volume":"95","author":"Y Kawakami","year":"2004","unstructured":"Kawakami Y, Fujita T, Matsuzaki Y, Sakurai T, Tsukamoto M, Toda M, Sumimoto H (2004) Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 95:784\u2013791","journal-title":"Cancer Sci"},{"key":"1044_CR12","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/0959-8049(96)00145-1","volume":"324","author":"PE Postmus","year":"1996","unstructured":"Postmus PE, Scagliotti G, Groen HJ, Gozzelino F (1996) Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EOGTC phase III trial. Eur J Cancer 324:1498\u20131503","journal-title":"Eur J Cancer"},{"key":"1044_CR13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01243894-200601000-00019","volume":"1","author":"EA Hirschowitz","year":"2006","unstructured":"Hirschowitz EA, Hiestand DM, Yannelli JR (2006) Vaccines for lung cancer. J Thorac Oncol 1:93\u2013104","journal-title":"J Thorac Oncol"},{"key":"1044_CR14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","volume":"332","author":"MEL Burg Van der","year":"1995","unstructured":"Van der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332:629\u2013634","journal-title":"N Engl J Med"},{"key":"1044_CR15","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3748\/wjg.14.1159","volume":"14","author":"HAH al-Shammaa","year":"2008","unstructured":"al-Shammaa HAH, Li Y, Yoneyama Y (2008) Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol 14:1159\u20131166","journal-title":"World J Gastroenterol"},{"key":"1044_CR16","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1245\/s10434-007-9350-7","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Sim J, Morris DL (2007) Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol 14:1807\u20131817","journal-title":"Ann Surg Oncol"},{"key":"1044_CR17","first-page":"3303","volume":"24","author":"T Kaneko","year":"2004","unstructured":"Kaneko T, Goto S, Kushima Y, Miyamoto J, Eriguchi M, Nieda M, Egawa K (2004) A report of three patients treated with immunocell therapy with imatinib mesylate. Anticancer Res 24:3303\u20133310","journal-title":"Anticancer Res"},{"issue":"S","key":"1044_CR18","first-page":"439","volume":"94","author":"K Yagita","year":"2003","unstructured":"Yagita K, Maruyama S, Sukegawa Y, Takenoshita S, Kanazawa M, Katoh R, Hagi H, Fujimoto S (2003) A role of immunotherapy for progress of molecular target on treatment of lung adenocarcinoma. Cancer Sci 94(S):439","journal-title":"Cancer Sci"},{"key":"1044_CR19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1479-5876-8-53","volume":"8","author":"H Norell","year":"2010","unstructured":"Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Picchocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R (2010) Vaccination with a plasmid DNA encoding HER-2\/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 8:53\u201364","journal-title":"J Transl Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1044-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-011-1044-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1044-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:33:10Z","timestamp":1558715590000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-011-1044-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,3]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1007\/s00262-011-1044-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,3]]}}}